Article Text

Download PDFPDF
Effects of hormone therapy on quality of life in postmenopausal women with CAD differed according to menopausal symptoms

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: Does hormone therapy (HT) improve health-related quality of life (HRQL) in postmenopausal women with coronary artery disease (CAD)?


Randomised {allocation concealed*}, blinded {patients, clinicians, data collectors, and outcome assessors}*, placebo-controlled trial with follow up to 3 years.


Outpatient and community settings at 20 US clinical centres.


2763 postmenopausal women <80 years of age (mean age 67 y) with documented CAD (previous myocardial infarction [MI], >50% luminal narrowing of a major vessel on angiography, or a previous coronary revascularisation procedure). Exclusion criteria were MI or revascularisation procedure in the past 6 months, previous hysterectomy, contraindications to HT, HT in the previous 3 months, or life-threatening illness. 2762 patients (99.9%) were included in the analysis; 2246 (81%) had HRQL data for all time points (baseline, 4 mo, 1 y, and 3 y).


1380 women were allocated to HT (0.625 mg of conjugated equine oestrogens and 2.5 mg of medroxyprogesterone acetate [Prempro, …

View Full Text


  • A modified version of this abstract also appears in Evidence-Based Mental Health and Evidence-Based Nursing.

  • Source of funding: Wyeth-Ayerst Research.

  • For correspondence: Dr MA Hlatky, Stanford University, School of Medicine, Stanford, CA, USA. E-mail hlatky{at}

  • Hulley S, Grady D, Bush T, et al. JAMA 1998;280:605–13.

  • Information provided by author.

  • * See glossary.